Novartis Applauds Quebec’s Move to Reimburse Families for Zolgensma

Novartis Applauds Quebec’s Move to Reimburse Families for Zolgensma

311366

Novartis Applauds Quebec’s Move to Reimburse Families for Zolgensma

Novartis Pharmaceuticals Canada is lauding the province of Quebec for its decision to provide public reimbursement for Zolgensma (onasemnogene abeparvovec), an approved gene therapy for spinal muscular atrophy (SMA) in children. Zolgensma is the first gene therapy to receive formal public reimbursement in Canada. The current recommendation follows that of the Institut national d’excellence en santé et services sociaux (INESSS) made earlier this year, which includes a pathway for children up to six months old…

You must be logged in to read/download the full post.